selinexor and ruxolitinib for Myelofibrosis: Biotech Catalysts Nov 9, 2026

This week, we turn our attention to Karyopharm Therapeutics’ selinexor plus ruxolitinib, a significant catalyst in myelofibrosis treatment. With approval odds at 68% and pivotal data expected on December 13, 2026, this combination therapy is one to watch. The SENTRY trial results will be crucial in determining its impact on treatment paradigms for JAK inhibitor-naïve patients.

The full biotech catalysts to watch

Selinexor plus Ruxolitinib: A New Frontier in Myelofibrosis Treatment

The selinexor and ruxolitinib combination offers a fresh approach for JAK inhibitor-naïve myelofibrosis patients. The Phase 3 SENTRY study evaluated 353 patients, showing 49.8% achieved the primary endpoint of spleen-volume reduction at Week 24, compared to 28.0% with ruxolitinib alone. This results in an odds ratio of 2.58, with a p-value of less than 0.0001, marking significant efficacy. Yet, missing the symptom endpoint raises questions about overall benefits. The upcoming Week 48 analysis will be pivotal for understanding response durability and safety, critical given selinexor's known side effects such as cytopenias and gastrointestinal issues. With a global commercial opportunity estimated at $1.0 to $2.0 billion, the unmet need is clear. To capture market share against existing therapies, selinexor must demonstrate benefits beyond spleen volume reduction.

Selinexor Monotherapy: The SENTRY-2 Study’s Ambiguous Promise

Beyond combination therapy, Karyopharm is exploring selinexor monotherapy in the SENTRY-2 study for JAK inhibitor-naïve myelofibrosis patients. This Phase 2 trial with 29 patients at a 60 mg weekly dose carries just a 12% approval probability. The absence of a randomized control and limited efficacy data is concerning. The primary endpoint is spleen-volume reduction, but without measures like overall survival or progression-free survival, confidence is low. The market is competitive, with established JAK inhibitors. Selinexor's differentiation is its unique mechanism as a selective exportin-1 inhibitor, yet the trial's small size and unblinded design pose risks. Without clear regulatory designations or strong efficacy data, selinexor monotherapy's future is uncertain.

SMd: A Combination Therapy for Relapsed/Refractory Multiple Myeloma

Karyopharm's selinexor, mezigdomide, and dexamethasone (SMd) combination is being tested in STOMP Arm 12 for relapsed/refractory multiple myeloma (RRMM). This Phase 1b/2 study examines safety and preliminary efficacy of this oral regimen. Preliminary results show a 40% overall response rate, with four patients achieving very good partial responses. However, the lack of strong survival data and high rates of neutropenia and thrombocytopenia are challenges. The global RRMM therapy market is valued at $10-15 billion, presenting a major opportunity, but SMd must show clear clinical benefits amid tough competition. The PoA for this combination is 12%, indicating the need for more data to back its efficacy and safety.

Emavusertib: A Cautious Look at CLL Potential

Curis, Inc.'s emavusertib (CA-4948) is being tested in various hematologic malignancies, but its role in Chronic Lymphocytic Leukemia (CLL) remains unclear due to the lack of a Phase 2 program for this indication. While promising in areas like Acute Myeloid Leukemia, the absence of CLL-specific data complicates its market position. The CLL market is estimated at $8 billion to $12 billion annually, showing unmet needs, especially for patients resistant to current therapies. However, without clinical data for CLL, the PoA is -1%, highlighting the risks of investing in emavusertib for CLL without clear evidence or regulatory backing.

The Biotech Catalyst Calendar: Key Dates Ahead

Several key biotech dates are approaching. The pivotal data readout for selinexor plus ruxolitinib is set for December 13, 2026, which could significantly affect Karyopharm's valuation. Selinexor monotherapy results from the SENTRY-2 study will be released a day earlier, on December 12, 2026. Outcomes of these trials will be crucial for Karyopharm's myelofibrosis programs. Other catalysts include ongoing trials for emavusertib in hematologic malignancies, though its relevance to CLL is questionable. Investors should monitor these dates for potential market shifts based on trial results.

Risks and Opportunities in the Biotech Landscape

The biotech landscape presents both risks and opportunities, especially with the catalysts we're monitoring. For Karyopharm, safety concerns related to selinexor are significant, given adverse events reported in past studies. Upcoming data will be crucial to determine if benefits outweigh these risks. The competitive landscape, with established therapies, adds pressure on Karyopharm to provide compelling efficacy and safety evidence. However, commercial opportunities in myelofibrosis and multiple myeloma markets are substantial, provided therapies show meaningful clinical benefits. Investors must carefully weigh these factors when considering positions in Karyopharm and other biotech firms.

The bottom line

Staying informed about these catalysts is crucial for making strategic investment decisions.